Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Yamashita, Fumie ^a   Azuma, Koichi ^a   Yoshida, Tsukasa ^a   Yamada, Kazuhiko ^a   Kawahara, Akihiko ^b   Hattori, Satoshi ^c   Takeoka, Hiroaki ^a   Zaizen, Yoshiaki ^a   Kawayama, Tomotaka ^a   Kage, Masayoshi ^b   Hoshino, Tomoaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; EGFR GENE; ERCC1 GENE; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL TIME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84881161098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071356     Document Type: Article

References (25)

1. Parkin DM, Bray FI, Devasa SS, (2001) Cancer burden in the year 2000: the global picture. Eur J Cancer 37: 4-66.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl Med 350: 2129-39.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-500.
4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-8.
5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11: 121-8.
6. Rafael R, Carcereny E, Gervais R, Vergnenegre A, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol 13: 239-46.
7. Zhou C, Wu YL, Chen G, Feng J, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study. Lancet Oncol 12: 735-42.
8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-57.
9. Lin CC, Hsu HH, Sun CT, Shih JY, Lin ZZ, et al. (2010) Chemotherapy response in east Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. J Thorac Oncol 5: 1424-1429.
10. Hotta K, Kiura K, Toyooka S, Takigawa N, Soh J, et al. (2007) Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in japanease patients with non-small cell lung cancer. J Thor Oncol. 2: 632-637.
11. Wu M, Zhao J, Song SW, Zhuo M, Wang X, et al. (2010) EGFR mutations are associated with but not with the response to front-line chemotherapy in the chinese patients with advanced non-small cell lung cancer. Lung Cancer 67: 343-347.
12. Park JH, Lee SH, Keam B, Kim TM, Kim DW, et al. (2012) EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer 77: 433-437.
13. Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, et al. (2010) Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 69: 110-115.
14. Hubner RA, Riley RD, Billingham LJ, Popat S, (2011) Excision repair cross-complementation group1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PloS ONE 6: e25164.
15. Besse B, Olaussen KA, Soria JC, (2013) ERCC1 and RRM1 for prime time? J Clin Oncol 31: 1050-60.
16. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S,et al. (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64; 326-333.
17. Gandara DR, Grimminger P, Mack PC, Lala PN Jr, Li T, et al. (2010) Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 5: 1933-1938.
18. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, et al. (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-82.
19. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, et al. (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor exon 19 and exon21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844.
20. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, et al. (2006) Exon19 deletion mutations of epidermal growth factor reseptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12: 3908-3914.
21. Ren S, Chen X, Kuang P, Zheng L, Su C, et al. (2012) Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker woman with pulmonary adenocarcinoma. Cancer 118: 5588-94.
22. Lee KH, Min HS, Han SW, Oh DY, Lee SH, et al. (2008) ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 60: 401-407.
23. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-23.
24. Simon GR, Sharma S, Cantor A, Smith P, Bepler G, (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127: 978-983.
25. Kawahara A, Azuma K, Hattori S, Nakashima K, Basaki Y, et al. (2010) The close correlation between 8-hydroxy-2,-deoxyguanosine and epidermal growth factor reseptor activating mutation in non-small cell lung cancer. Human Pathology 41: 951-959.